https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53520 28.4 ng/mL) was independently associated with older age, use of beta-blockers, and number of MACE events within a 1 year period. In this patient cohort, elevated sST2 levels are associated with unplanned hospital admission due to MACE within 1 year, independent of the nature of the index cardiovascular admission.]]> Wed 28 Feb 2024 15:31:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52044 Wed 27 Sep 2023 10:07:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50848 Wed 09 Aug 2023 09:31:56 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49072 Wed 03 May 2023 16:08:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49049 Wed 03 May 2023 15:40:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41950 20 mm Hg and pulmonary capillary wedge pressure >15 mm Hg during right heart catheterization. LHD may lead to elevated left atrial pressure alone, which in the absence of intrinsic pulmonary vascular disease will result in PH without changes in pulmonary vascular resistance. Persistent elevation in left atrial pressure may, however, also be associated with subsequent pulmonary vascular remodeling, vasoconstriction, and an increase in pulmonary vascular resistance. Hence, there are 2 subgroups of PH due to LHD, isolated postcapillary PH and combined post- and precapillary PH, with these groups have differing clinical implications. Differentiation of pulmonary arterial hypertension and PH due to LHD is critical to guide management planning; however, this may be challenging. Older patients, patients with metabolic syndrome, and patients with imaging and clinical features consistent with left ventricular dysfunction are suggestive of LHD etiology rather than pulmonary arterial hypertension. Hemodynamic measures such as diastolic pressure gradient, transpulmonary gradient, and pulmonary vascular resistance may assist to differentiate pre- from postcapillary PH and offer prognostic insights. However, these are influenced by fluid status and heart failure treatment. Pulmonary arterial hypertension therapies have been trialed in the treatment with concerning results reflecting disease heterogeneity, variation in inclusion criteria, and mixed end point criteria. The aim of this review is to provide an updated definition, discuss possible pathophysiology, clinical aspects, and the available treatment options for PH due to LHD.]]> Tue 16 Aug 2022 14:31:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53262 Mon 20 Nov 2023 12:14:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48470 Fri 17 Mar 2023 15:08:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41547 Fri 05 Aug 2022 14:23:18 AEST ]]>